Surrozen (SRZN) Total Liabilities (2020 - 2026)
Surrozen (SRZN) posted quarterly Total Liabilities of $398.9 million for Q1 2026, up 265.4% year-over-year from $109.2 million in Q1 2025, and up 39.22% quarter-over-quarter from $286.5 million in Q4 2025.
Surrozen (SRZN) Total Liabilities (2020 - 2026) Analysis & Trends
Surrozen's Total Liabilities history runs 7 years deep, the most recent figure standing at $398.9 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 265.4% year-over-year to $398.9 million; the TTM figure through Mar 2026 stood at $398.9 million (up 265.4% YoY), while the FY2025 annual figure was $286.5 million, up 310.17% from the prior year.
- Total Liabilities for Q1 2026 stood at $398.9 million, up from $286.5 million in the prior quarter.
- The five-year high for Total Liabilities was $398.9 million in Q1 2026, with the low at $6.6 million in Q1 2024.
- The 5-year median for Total Liabilities is $15.0 million (2022), against an average of $71.7 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities slumped 51.1% in 2022, then surged 1558.89% in 2025.
- Surrozen's Total Liabilities stood at $13.4 million in 2022, then tumbled by 39.37% to $8.1 million in 2023, then soared by 757.54% to $69.8 million in 2024, then soared by 310.17% to $286.5 million in 2025, then soared by 39.22% to $398.9 million in 2026.
- Business Quant data shows SRZN's Total Liabilities at $398.9 million in Q1 2026, $286.5 million in Q4 2025, and $117.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 334.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 334.27 Mn |
| Mar 31, 2026 | 398.86 Mn |
| Dec 31, 2025 | 286.49 Mn |
| Sep 30, 2025 | 117.56 Mn |
| Jun 30, 2025 | 55.58 Mn |
| Mar 31, 2025 | 109.16 Mn |
| Dec 31, 2024 | 69.85 Mn |
| Sep 30, 2024 | 42.33 Mn |
| Jun 30, 2024 | 39.01 Mn |
| Mar 31, 2024 | 6.58 Mn |
| Dec 31, 2023 | 8.15 Mn |
| Sep 30, 2023 | 8.44 Mn |
| Jun 30, 2023 | 8.94 Mn |
| Mar 31, 2023 | 11.16 Mn |
| Dec 31, 2022 | 13.43 Mn |
| Sep 30, 2022 | 13.94 Mn |
| Jun 30, 2022 | 14.43 Mn |
| Mar 31, 2022 | 14.99 Mn |
| Dec 31, 2021 | 27.47 Mn |
| Sep 30, 2021 | 26.91 Mn |